Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics announces regulatory approval to expand its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma to South Korea and Australia, increasing the trial sites globally from over 60 to more than 80. Interim results show promising minimal residual disease clearance and a favorable safety pr…